Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis | MicrobiomeTrials← Back to trialsNCT06430671
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
CompletedPHASE1INTERVENTIONAL
Trial Details
Start: 2024-06-18Est. Completion: 2025-12-23
Enrollment target: 11 participants Locations- RS Centrum - Neurologická klinika, Prague, Czechia
- Neurologická klinika 2. LF UK a FN Motol, Prague, Czechia
- Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP), Göttingen, Lower Saxony, Germany
- Universitätsklinikum Münster (UKM), Klinik für Neurologie, Münster, North Rhine-Westphalia, Germany
- Universitätsklinikum Hamburg-Eppendorf (UKE), Klinik für Neurologie, Hamburg, Germany
- Azienda Ospedaliero Universitaria Careggi, Florence, Tuscany, Italy
- Bellevue Medical Group (BMG), Neurozentrum, Zurich, Switzerland
- UniversitätsSpital Zürich (USZ), Klinik für Neurologie, Zurich, Switzerland
Other microbiome trials you might be interested in
Relapsing-remitting Multiple Sclerosis (RRMS)
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US…
Mobile, United StatesEst. completion Jan 15, 2027
Multiple SclerosisRRMSRelapsing Remitting MS
The main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclero…
San Francisco, United StatesEst. completion Dec 1, 2029